Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 272

1.

Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.

Holla ØL, Cameron J, Berge KE, Kulseth MA, Ranheim T, Leren TP.

Scand J Clin Lab Invest. 2006;66(4):317-28.

PMID:
16777760
[PubMed - indexed for MEDLINE]
2.

Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.

Strøm TB, Holla ØL, Cameron J, Berge KE, Leren TP.

Clin Chim Acta. 2010 Feb;411(3-4):229-33. doi: 10.1016/j.cca.2009.11.008. Epub 2009 Nov 13.

PMID:
19917273
[PubMed - indexed for MEDLINE]
3.

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, Leren TP.

Hum Mol Genet. 2006 May 1;15(9):1551-8. Epub 2006 Mar 28.

PMID:
16571601
[PubMed - indexed for MEDLINE]
Free Article
4.

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, Trillard M, Abifadel M, Tebon A, Attie AD, Rader DJ, Boileau C, Brissette L, Chrétien M, Prat A, Seidah NG.

J Biol Chem. 2004 Nov 19;279(47):48865-75. Epub 2004 Sep 9.

PMID:
15358785
[PubMed - indexed for MEDLINE]
Free Article
5.

Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.

Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A, De Francesco R, Wright SD, Sparrow CP, Carfi A, Sitlani A.

J Biol Chem. 2007 Jul 13;282(28):20502-12. Epub 2007 May 10.

PMID:
17493938
[PubMed - indexed for MEDLINE]
Free Article
6.

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD.

J Clin Invest. 2006 Nov;116(11):2995-3005.

PMID:
17080197
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.

Holla ØL, Cameron J, Berge KE, Ranheim T, Leren TP.

BMC Cell Biol. 2007 Mar 1;8:9.

PMID:
17328821
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Nonsense-mediated decay of human LDL receptor mRNA.

Holla ØL, Kulseth MA, Berge KE, Leren TP, Ranheim T.

Scand J Clin Lab Invest. 2009;69(3):409-17. doi: 10.1080/00365510802707163.

PMID:
19148831
[PubMed - indexed for MEDLINE]
9.

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

McNutt MC, Lagace TA, Horton JD.

J Biol Chem. 2007 Jul 20;282(29):20799-803. Epub 2007 May 29.

PMID:
17537735
[PubMed - indexed for MEDLINE]
Free Article
10.

Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.

Herbert B, Patel D, Waddington SN, Eden ER, McAleenan A, Sun XM, Soutar AK.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1333-9. doi: 10.1161/ATVBAHA.110.204040. Epub 2010 May 6.

PMID:
20448210
[PubMed - indexed for MEDLINE]
Free Article
11.

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.

Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG.

J Biol Chem. 2008 Jan 25;283(4):2363-72. Epub 2007 Nov 26.

PMID:
18039658
[PubMed - indexed for MEDLINE]
Free Article
12.

The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation.

Noguchi T, Katsuda S, Kawashiri MA, Tada H, Nohara A, Inazu A, Yamagishi M, Kobayashi J, Mabuchi H.

Atherosclerosis. 2010 May;210(1):166-72. doi: 10.1016/j.atherosclerosis.2009.11.018. Epub 2009 Nov 20.

PMID:
20006333
[PubMed - indexed for MEDLINE]
13.

Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.

Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.

Transl Res. 2012 Aug;160(2):125-30. doi: 10.1016/j.trsl.2012.01.010. Epub 2012 Jan 31.

PMID:
22683370
[PubMed - indexed for MEDLINE]
14.

A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.

Lin J, Wang LY, Liu S, Wang XM, Yong Q, Yang Y, DU LP, Pan XD, Wang X, Jiang ZS.

Chin Med J (Engl). 2010 May 5;123(9):1133-8.

PMID:
20529551
[PubMed - indexed for MEDLINE]
Free Article
15.

Functional analysis of sites within PCSK9 responsible for hypercholesterolemia.

Pandit S, Wisniewski D, Santoro JC, Ha S, Ramakrishnan V, Cubbon RM, Cummings RT, Wright SD, Sparrow CP, Sitlani A, Fisher TS.

J Lipid Res. 2008 Jun;49(6):1333-43. doi: 10.1194/jlr.M800049-JLR200. Epub 2008 Mar 19.

PMID:
18354137
[PubMed - indexed for MEDLINE]
Free Article
16.

Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.

Leren TP.

Clin Genet. 2004 May;65(5):419-22.

PMID:
15099351
[PubMed - indexed for MEDLINE]
17.

A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.

Holla ØL, Strøm TB, Cameron J, Berge KE, Leren TP.

Mol Genet Metab. 2010 Feb;99(2):149-56. doi: 10.1016/j.ymgme.2009.09.012. Epub 2009 Sep 27.

PMID:
19828345
[PubMed - indexed for MEDLINE]
18.

[Identification of a novel mutation at the point of low density lipoprotein receptor gene from a subject with familial hypercholesterolemia].

Liu YR, Tao QM, Chen JZ, Tao M, Guo XG, Shang YP, Zhu JH, Zhang FR, Zheng LR, Wang XX.

Sheng Li Xue Bao. 2004 Oct 25;56(5):566-72. Chinese.

PMID:
15497035
[PubMed - indexed for MEDLINE]
Free Article
19.

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M.

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1448-53. Epub 2004 May 27.

PMID:
15166014
[PubMed - indexed for MEDLINE]
Free Article
20.

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.

Berge KE, Ose L, Leren TP.

Arterioscler Thromb Vasc Biol. 2006 May;26(5):1094-100. Epub 2006 Jan 19.

PMID:
16424354
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk